Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss	$ (623,035)	$ (1,300,112)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		4,596
Amortization	106,203	106,203
Lease expense	5,172	1,070
Stock-based compensation – employees	75,750	196,650
Shares issued for interest	62,100	32,400
Foreign exchange loss (gain)	24,725	(128,710)
Changes in operating assets and liabilities which provided (used) cash
Other receivable	42,730	(2,054)
Accounts payable	27,522	2,466
Accounts payable – related parties		8,347
Accrued interest – related and non-related parties	186,505	867,731
Accrued expenses	31,200	31,200
Net cash used in operating activities	(61,128)	(180,213)
Cash flows used in investing activities
Advances to CEN Biotech Ukraine LLC	(50,000)
Cash flows provided by financing activities
Issuance of convertible notes	110,000	178,000
Net decrease in cash and cash equivalents	(1,128)	(2,213)
Cash and cash equivalents, beginning of period	1,908	3,757
Cash and cash equivalents, end of period	780	1,544
Non-cash transactions - investing and financing activities
Issuance of common stock - settlement of accrued liability	$ 13,390